Scilex Holding Company has filed a Certificate of Designation for 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock, allowing holders to receive a dividend based on shares of its subsidiary Semnur Pharmaceuticals, with a potential value of up to $200 million, contingent on market conditions.